COHIVE: Coronavirus (COVID-19) Outcomes in HIV Evaluation in Resource Limited Settings

NCT04371835 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 596

Last updated 2022-03-18

No results posted yet for this study

Summary

COHIVE is an observational cohort nested in four antiretroviral therapy research studies (ADVANCE - NCT03122262; D²EFT - NCT03017872; DolPHIN2 - NCT03249181 and NAMSAL-ANRS12313 - NCT02777229). COHIVE will include participants who are possible COVID-19 cases with symptoms or confirmed COVID-19 cases, and participants who agree to have a serology testing for SARS-CoV-2 regardless of COVID-19 history.

Conditions

  • HIV-infection/Aids
  • Coronavirus Infection

Sponsors & Collaborators

  • University of Witwatersrand, South Africa

    collaborator OTHER
  • University of Liverpool

    collaborator OTHER
  • Université Montpellier

    collaborator OTHER
  • UNITAID

    collaborator OTHER
  • ViiV Healthcare

    collaborator INDUSTRY
  • Kirby Institute

    lead OTHER_GOV

Principal Investigators

  • Alexandra Calmy, MD, PhD · University Hospital, Geneva

  • Eric Delaporte, MD, PhD · IRD, Inserm, University of Montpellier

  • Saye Khoo, MD, PhD · University of Liverpool

  • Emmanuelle Papot, MD · Kirby Institute

  • Mark Polizzotto, MD, PhD · Kirby Institute

  • Francois WD Venter, MD · Wits Reproductive Health and HIV Institute

  • Joana Woods, MD · Wits Reproductive Health and HIV Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-12
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Argentina
  • Brazil
  • Cameroon
  • India
  • Malaysia
  • Nigeria
  • South Africa
  • Thailand
  • Uganda
  • Zimbabwe

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04371835 on ClinicalTrials.gov